Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone

Journal of Pharmaceutical Sciences

Volumn 96, Issue 1, 2007, Pages 27-37

  Vogt, M ^a   Derendorf, H ^b   Kramer J ^c   Junginger, H E ^d   Midha, K K ^e   Shah, V P ^f   Stavchansky, S ^g   Dressman, J B ^a   Barends, D M ^h  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c PHAST GmbH   (Germany)

^d NARESUAN UNIVERSITY   (Thailand)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f International Pharmaceutical Federation FIP   (Netherlands)

^g UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Absorption; Bioequivalence; Biopharmaceutics Classification System (BCS); Permeability; Prednisolone; Regulatory science; Solubility

Indexed keywords

PREDNISOLONE; PREDNISONE;

ALLERGIC DISEASE; AREA UNDER THE CURVE; ARTHRITIS; ASTHMA; BIOEQUIVALENCE; CONGENITAL ADRENAL HYPERPLASIA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EXCRETION; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; HEPATITIS; IN VIVO STUDY; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; REVIEW; SHOCK; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 33846162254     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20768     Document Type: Note

References (77)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on Biopharmaceutics Classification System (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93:1945-1956.
2. WHO. 2005. Model list of essential medicines, 14th edition. Available from URL http://whqlibdoc. who.int/hq/2005/a87017_eng.pdf
3. WHO. 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert committee on specifications for pharmaceutical preparations. Available from URL http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf.
4. Kalantzi L, Reppas C, Dressman JB, Amidon G, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (Paracetamol). J Pharm Sci 95:4-14.
5. Manzo HR, Olivera ME, Amidon GL, Dressman JB, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Amitriptyline hydrochloride. J Pharm Sci 95:966-973.
6. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate and chloroquine hydrochloride. J Pharm Sci 94:1389-1395.
7. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midka KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sci 95:974-984.
8. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 94:2121-2131.
9. Kortejärvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride. J Pharm Sci 94:1617-1625.
10. Francisco GE, Honigberg IL, Stewart JT, et al. 1984. In vitro and in vivo bioequivalence of commercial prednisone tablets. Biopharm Drug Dispos 5:335-344.
11. Pickup ME. 1979. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokin 4:111-128.
12. Rote Liste. 2004 Online. Häßner K, editor. Frankfurt, Germany: Rote Liste Service GmbH, Available from URL www.rote-liste.de
13. Fachinformation DH. 2002. Bundesverband der Pharmazeutischen Industrie Service GmbH, Aulendorf, Germany.
14. Kaiser H, Kley HK. 2002. Cortisontherapie. Corticoide in Klinik und Praxis. 11. Auflage. Georg Thieme Verlag, Stuttgart, Germany.
15. Salem M, Tainsh RE, Jr., Bromberg J, Loriaux DL, Chernow B. 1994. Perioperative glucocorticoid coverage. A reasessment 42 years after emergence of a problem. Ann Surg 219:416-425.
16. O'Driscoll BR, Kalra S, Wilson M, Pickering CA, Carroll KB, Woodcock AA. 1993. Double-blind trial of steroid tapering in acute asthma. Lancet 341:324-327.
17. Hatton MQF, Vathenen AS, Allen MJ, Davies S, Cooke NJ. 1995. A comparison of 'abruptly stopping' with 'tailing off' oral corticosteroids in acute asthma. Respir Med 89:101-104.
18. Wenning GK, Wietholter H, Schnauder G, Muller PH, Kanduth S, Renn W. 1994. Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS. Acta Neurol Scand 89:270-273.
19. USP 28-NF 23. 2005. The United States Pharmacopeia-The National Formulary. Rockville, MD: The United States Pharmacopeial Convention, Inc.
20. European Directorate for the Quality of Medicines. European pharmacopoeia, 5th edition. Strasbourg, France, European Directorate for the Quality of medicines, Council of Europe, Strasbourg, France.
21. Veiga MD, Cadorniga R, Lozano R. 1985. Thermal study of prednisolone polymorphe. Thermochim Acta 96:111-115.
22. Kuhnert-Brandstätter M. 1977. Polymorphe und pseudopolymorphe Kristallformen von Steroidhormonen. Pharm Ind 39:377-383.
23. Yang G, Ran Y, Yalkowsky SH. 2002. General solubility equation and the method using an amended salvation energy relationship. J Pharm Sci 91:517-533.
24. Ran Y, Yalkowsky SH. 2001. Prediction of aqueous solubility of organic compounds by the general solubility equation (gse). J Chem Inf Comput Sci 41:1208-1217.
25. Hayton WL, Guttman DE, Levy G. 1972. Effect of complex formation on drug absorption XI: Complexation of prednisone and prednisolone with dialkylpropionamides and its effect on prednisone transfer through an artificial lipoid barrier. J Pharm Sci 61:356-361.
26. Sjoblom L. 1967. Pharmaceutical applications and physiological aspects of solubilisation in solvent properties of surfactant solutions. In: Shinoda K, editor. Solvent Properties of Surfactant Solutions. New York: Dekker, pp 189-247.
27. Machatha SG, Yalkowsky SH. 2005. Comparison of the octanol/water partition coefficients calculated by ClogP®, ACDlogP and KowWin® to experimentally determined values. Int J Pharm 294:185-192.
28. Faassen F, Kelder J, Lenders J, Onderwater R, Vromans H. 2003. Physicochemical properties and transport of steroids across Caco-2 cells. Pharm Res 20:177-186.
29. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85-96.
30. Petereit LB, Meikle AM. 1977. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 22:912-916.
31. Tanner A, Bochner F, Caffin J, Halliday J, Powell L. 1979. Dose dependent prednisolone kinetics. Clin Pharmacol Ther 25:571-578.
32. Al-Habet S, Rogers HJ. 1980. Pharmacokinetics of intravenous and oral prednisolone. Br J Clin Pharmacol 10:503-508.
33. Bergrem H, Grottum P, Rugstad HE. 1983. Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Eur J Clin Pharmacol 24:415-419.
34. Gambertoglio JG, Vicenti F, Feduska NJ, Birnbaum J, Salvetierra O, Amend WJC. 1980. Prednisolone disposition in cushingoid and non-cushingoid kidney transplant patients. J Clin Endocrinol Metab 51:561-565.
35. Frey BM, Frey FJ. 1990. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 19:126-146.
36. Täuber U, Haack D, Nieuweboer B, Kloos G, Vescei P, Wendt H. 1984. The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 22:48-55.
37. Frey FJ, Horber FF, Frey BM. 1988. Altered metabolism and decreased efficacy of prednisolone and prednisone in patients with hyperthyroidism. Clin Pharmacol Ther 44:510-521.
38. Frey FJ, Amend WJC, Frey BM, Herford NHG, Benet LZ. 1981. Pharmacokinetics and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients. Eur J Clin Pharmacol 21:235-242.
39. Luippold G, Benöhr P, Schneider S, Marto M, Mühlbauer B. 2001. Bioequivalence of different prednisolone tablet formulations. Arzneim Forsch Drug Res 51:638-642.
40. Jenkins JS, Sampson PA. 1967. Conversion of cortisone to cortisol and prednisone to prednisolone. Br Med J 1:205-207.
41. Powell LW, Axelson E. 1972. Corticosteroids in liver disease: Studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut 13:690-696.
42. Sullivan TJ, Hallmark MR, Sakmar E, Weidler DJ, Earhart RH, Wagner JG. 1976. Comparative bioavailability: Eight commercial prednisone tablets. J Pharmacokinet Biopharm 4:157-172.
43. Tembo AV, Hallmark MR, Sakmar E, et al. 1977. Bioavailability of prednisolone tablets. J Pharmacokinet Biopharm 5:257-270.
44. Rose JQ, Yurchak AM, Jusko WJ. 1981. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 9:389-417.
45. Hulme B, James VH, Rault R. 1975. Absorption of enteric and non-enteric coated prednisolone tablets. Br J Clin Pharmacol 2:317-320.
46. Al-Habet S, Rogers HJ. 1989. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. Eur J Clin Pharmacol 37:423-426.
47. Prokein R. 1982. Zur Pharmakokinetik des Prednisolons: Einfluss unterschiedlicher Kostformen auf die enterale Resorption. Inaugural- Dissertation, Görich & Weiershäuser Druck, Marburg.
48. Avdeef A, Ruell J, Du C. 2002. PAMPA structure-permeability relations of several steroids: Development of the high-throughput gastrointestinal and blood-brain barrier transport models. Available from URL: http://pion-inc.com/ images/Gastro-BBBPAMPA2002.pdf
49. Pickup ME, Lose JR, Leatham PA, Rhind VM, Wright V, Downie WW. 1977. Dose dependent pharmacokinetics of prednisolone. Eur J Clin Pharmacol 12:213-219.
50. Brien TG. 1981. Human corticosteroid binding globulin. Glin Endocrinol Oxf 14:193.
51. Frey FJ. 1987. Kinetics and dynamics of prednisolone. Endocr Rev 8:453-473.
52. Steele WH, Hawksworth GM, Barber HE. 1982. The binding of prednisolone in human serum and to recrystallized human albumin in vitro. Br J Clin Pharmacol 14:667.
53. HagerROM. 2001. Springer Verlag. Heidelberg.
54. American Academy of Pediatrics. 2001. The transfer of drugs and other chemical into human milk. Pediatrics 108:776-789.
55. McKenzie SA, Selley JA, Agnew JE. 1975. Secretion of prednisolone into breast milk. Arch Dis Child 50:894-896.
56. Nugent CA, Eik-nes K, Tyler FH. 1959. A comparative study of the metabolism of hydrocortisone and prednisolone. J Clin Endocrinol Metab 19:526-534.
57. Hartiala J. 1976. Steroid metabolism in adult lung. Agents Actions 6:522-526.
58. Szefler SJ. 1989. General pharmacology of glucocorticoids. In: Schleimer RP, Claman HN, Oronsky AL, editors. Anti-inflammatory steroid action basic and clinical aspects. San Diego, California: Academic Press, Inc, pp 353-376.
59. Loo JCK, McGilveray IJ, Jordan N, Moffat J, Brien R. 1978. Dose-dependent pharmacokinetics of prednisone and prednisolone in man. J Pharm Pharmacol 30:736.
60. Legler UF, Frey FJ, Benet LZ. 1982. Prednisolone clearance at steady state in humans. J Clin Endocrinol Metab 55:762-767.
61. Cheng H, Jusko WJ. 1993. Pharmacokinetics of reversible metabolic systems. Biopharm Drug Dispos 14:721-766.
62. Morris HG. 1978. Pharmacology and corticosteroids in asthma. In: Middleton E, Jr., Reed C, Ellis E, editors. Allergy principles and practice. St. Louis: C.V. Mosby, pp 464-480.
63. Stjernholm MR, Katz FH. 1975. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. J Clin Endocrinol Metab 41:887-893.
64. Meffin PJ, Brooks PM, Sallustio BC. 1984. Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol 17:394-404.
65. Zürcher RM, Frey BM, Frey FJ. 1989. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 45:366-372.
66. Ferry JJ, Horvath AM, Bekersky I, Heath EC, Ryan CF, Colburn WA. 1988. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol 28:81-87.
67. Meffin PJ, Wing LM, Sallustio BC, et al. 1984. Alterations in prednisolone disposition as a result of oral contraceptive use and dose. Br J Clin Pharmacol 17:655-664.
68. Fachinformation Decortin H 10 mg. Available from URL: http://www.fachinfo.de/data/fi/jsearch/viewPDF?wirkstoff&1819371871.
69. Fachinformation Prednisolon-ratiopharm Tabletten. Available from URL: http://www.fachinfo.de/data/fi/jsearch/viewPDF?wirkstoff&1988247025.
70. Fachinformation Dermosolon. Available from URL: http://www.fachinfo.de/ data/fi/jsearch/viewPDF? wirkstoff&1988246888.
71. Chulski T, Forist AA. 1958. The effects of some solid buffering agents in aqueous suspension on prednisolone. J Am Pharm Assoc (Baltim) 47:553-555.
72. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2000. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Available from URL: http://www.fda.gov/cder/guidance/ 3618fnl.pdf.
73. Committee for Proprietary Medicinal Products (CPMP). 2001. Note for guidance on the investigation of bioavailability and bioequivalence. Available from URL: http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf.
74. WHO. 2006. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. Technical Report Series, No 937, 40th Report, Annex 7 of WHO Expert committee on specifications for pharmaceutical preparations. Available from URL: http://whqlibdoc.who.int/ trs/WHO_TRS_937_eng.pdf.
75. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58:265-278.
76. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
77. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.